Blueprint Medicines to Present Preliminary Data from Ongoing Phase 1 Clinical Trial for BLU-285 in Advanced Systemic Mastocytosis at 2016 ASH Annual Meeting
The accepted abstracts are listed below and are now available online on the ASH conference website: http://www.hematology.org/Annual-Meeting/.
Oral Presentation:
Date & Time:
Presentation Title: Preliminary Safety and Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM)
Session Title: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with Agents Other Than JAK Inhibitors
Abstract Number: 477
Location:
Poster Presentations:
Date & Time:
Presentation Title: Inhibitory Effects of Midostaurin and BLU-285 on Myeloid Progenitor Cells Derived from Patients with Multi-Mutated KIT D816V+ Advanced Systemic Mastocytosis
Session Title: 635. Myeloproliferative Syndromes: Basic Science: Poster I
Abstract Number: 1964
Location:
Date & Time:
Presentation Title: Systemic Mastocytosis Patient Experience from Mast Cell Connect, the First Patient-Reported Registry for Mastocytosis
Session Title: 904. Outcomes Research—Malignant Conditions: Poster III
Abstract Number: 4783
Location:
Conference Call information
About
Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit www.blueprintmedicines.com.
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-preliminary-data-from-ongoing-phase-1-clinical-trial-for-blu-285-in-advanced-systemic-mastocytosis-at-2016-ash-annual-meeting-300356731.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, KWilliams@blueprintmedicines.com, Media Relations: Rachel Hutman, W20 Group, 301-801-5540, rhutman@wcgworld.com